Maciej Jabłkowski

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

Medicine, Internal Medicine, Pharmacotherapy +12

The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients #

Robert Flisiak, S.V. Feinman, Maciej Jabłkowski et al. · Hepatology · 2009 · 222 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Real‐world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study

Robert Flisiak, Ewa Janczewska, Marta Wawrzynowicz‐Syczewska et al. · Alimentary Pharmacology & Therapeutics · 2016 · 99 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study

Scott Fung, Peter Kwan, Milotka Fabri et al. · Journal of Hepatology · 2016 · 61 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety

Henry Lik‐Yuen Chan, Young‐Suk Lim, Kosh Agarwal et al. · The American Journal of Gastroenterology · 2023 · 60 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17